Market Overview

UPDATE: Credit Suisse Initiates AbbVie at Neutral on Humira Dependence

Share:
Related ABBV
AbbVie Initiates Pivotal Phase 3 Study of Veliparib for Patients with Early-Stage Triple-Negative Breast Cancer
Enanta Pharmaceuticals Announces Additional Data from AbbVie's M13-393 Study to be Presented at Liver Meeting
Premarket Biotech Digest: Arrowhead Initiates Dosing, Vertex Orkambi Approval, Insider Sales (Seeking Alpha)

Credit Suisse initiated AbbVie (NYSE: ABBV) with a Neutral rating and a $37.00 price target.

Credit Suisse noted, "AbbVie's cross-currents imply minimal stock movement from current price. Growth is modest with 2013-2020 sales and EPS CAGR at 2% and 3% respectively and only 20% revenue contribution from the pipeline by 2020. Humira contribution to ABBV is significant; contribution to sales '13-20 is at minimum 50%, and over 70% to profits. Positives: ~9% free cash flow yield, 4.3% dividend yield, 11.9x P/E (pharma 2013 average 13.9x), options on elagolix, ABT-199 for lymphoma & business development (BD). Negatives: overdependence on Humira and long-term competitive threat from orals and biosimilars, HCV franchise expectations already realistic."

AbbVie closed at $75.39 on Wednesday.

Latest Ratings for ABBV

DateFirmActionFromTo
Jun 2015Piper JaffrayInitiates Coverage onOverweight
Jun 2015JefferiesMaintainsBuy
May 2015Morgan StanleyAssumesEqual-weight

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Analyst Ratings

 

Related Articles (ABBV)

Around the Web, We're Loving...

Get Benzinga's Newsletters